Clinical Trials
4 trialsNCT04947124 2025-01-20
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101
Qlaris Bio, Inc.
Phase 2 Completed
NCT05495269 2025-01-20
Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)
Qlaris Bio, Inc.
Phase 2 Completed
NCT03944447 2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2 Unknown
NCT01997255 2016-05-05
Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
Baylor College of Medicine
Phase 2 Withdrawn